NCT04874584

Brief Summary

The purpose of the study is to see whether or not a telephone/ text message intervention, delivered by a registered nurse, is helpful in managing symptoms and can also prevent dehydration caused by chemotherapy treatment when given together for patients with metastatic breast, colon, lung or prostate cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
34

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 30, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 5, 2021

Completed
6 months until next milestone

Study Start

First participant enrolled

October 27, 2021

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2023

Completed
Last Updated

June 2, 2023

Status Verified

May 1, 2023

Enrollment Period

1.6 years

First QC Date

April 30, 2021

Last Update Submit

May 31, 2023

Conditions

Keywords

symptom self-managementsymptom severityemotional support

Outcome Measures

Primary Outcomes (2)

  • Change in MDASI scores

    MD Anderson Symptom Inventory (MDASI) is a 19 item scale with a score range from 0-10 per symptom question that measures symptom severity plus symptom interference combined to measure total symptom burden. The higher score indicates worsening of symptoms.

    baseline, up to 12 weeks

  • Incidents of dehydration

    Incidents of unscheduled medical visits for IV hydration

    up to 12 weeks

Secondary Outcomes (7)

  • change in Chronic Disease Self-Efficacy Scale (CDSES) scores

    baseline, up to 12 weeks

  • change in Partners in Health Scale (PIHS) scores

    baseline, up to 12 weeks

  • Percentage of completed call or text message

    up to 12 weeks

  • Change in FACT-B Scores

    baseline, up to 12 weeks

  • Change in FACT-P Scores

    baseline, up to 12 weeks

  • +2 more secondary outcomes

Study Arms (2)

CTNSM Group

EXPERIMENTAL

Culturally Tailored Nurse Symptom Management group (CTNSM) - participants in the CTNSM group will receive one in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message during the first 12 weeks of standard of care chemotherapy. In addition, participants can receive standard of care chemotherapy education.

Behavioral: CTNSMBehavioral: Standard of Care Chemotherapy Education

Standard of Care (control) Group

ACTIVE COMPARATOR

Participants in the control group will only be receiving the standard of care chemotherapy education.

Behavioral: Standard of Care Chemotherapy Education

Interventions

CTNSMBEHAVIORAL

The Culturally Tailored Nurse-delivered telephone/text message symptom-management intervention (CTNSM) intervention is an in-person or telehealth face-to-face education session followed by a weekly telephone call and/or text message conducted for the first 12 weeks of standard of care chemotherapy .

CTNSM Group

Standard of Care chemotherapy education is a one-time patient education session about general treatment-related side effects patients can experience from chemotherapy and the interventions to mitigate the symptoms.

CTNSM GroupStandard of Care (control) Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Eligible for Chemotherapy for the first time (Previous \& Ongoing hormonal only treatment allowed OR Neoadjuvant \& Adjuvant chemotherapy regimens with 2+ drugs allowed)
  • \> 18 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • There are no life expectancy restrictions
  • Women of child-bearing potential are allowed in the study as long as they are eligible for the chemotherapy treatment.
  • Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if:

  • Patients on immunotherapy only will be excluded
  • Previous chemotherapy
  • Under 18 years old
  • Medically Diagnosed with a Cognitive Impairment. Rationale for excluding people with cognitive impairment is that they would not be able to fully participate in the self-management care aspects of the intervention via the telephone, nor provide informed consent.
  • No access to a telephone
  • Blind or Deaf; If subject is Hearing-impaired or illiterate, then the subject may have a family member participate as a telecommunication surrogate with them in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami Sylvester Comprehensive Cancer Ctr.

Miami, Florida, 33136, United States

Location

Related Links

MeSH Terms

Conditions

DehydrationSyndrome

Condition Hierarchy (Ancestors)

Water-Electrolyte ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsDisease

Study Officials

  • Natasha Solle, PhD

    University of Miami

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant research professor

Study Record Dates

First Submitted

April 30, 2021

First Posted

May 5, 2021

Study Start

October 27, 2021

Primary Completion

May 31, 2023

Study Completion

May 31, 2023

Last Updated

June 2, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations